Purpose/Objective: Dynamic MLC (DMLC) tracking has been shown to successfully mitigate the dosimetric effects of intra-fraction organ motion and restore the target dose for standard flat treatment beams. Going forward, the introduction of a new generation of treatment devices with restricted couch-shift possibilities (MR-Linac) raises the question of whether DMLC tracking with a non-flat flatteningfilter free (FFF) treatment beam is feasible and safe if a moving target is positioned at an offset to the isocenter. This study investigates the dosimetric accuracy of 6X FFF DMLC tracking for an SBRT treatment of a lung cancer case with a peripherally located target using step-and-shoot IMRT and VMAT deliveries on an Elekta Synergy linac. Materials and Methods: We generated two hypo-fractionated treatment plans (3x18 Gy) with similar dose conformity in the target (34 cm 3 PTV) and a set of common planning constraints following the RTOG guidelines: a 15-beam step-and-shoot IMRT delivery, and a single arc VMAT delivery created in Pinnacle3 using SmartArc. The isocenter was shifted both 4 cm laterally to the left and in the anterior direction. The shift was chosen so that the center of the PTV would coincide with the high-gradient region of the FFF beam profile. The treatment plans were then delivered -with and without tracking -to the Delta4 verification device, which was mounted on a 4d motion platform. The deliveries were repeated under three breathing conditions: no motion, sin(t), and sin(t) with a 1mm/min baseline drift. Motion was limited to the sup-inf direction with a peak-to-peak amplitude of 20 mm and a time period of 4s. Dose measured for the static deliveries (no motion) were used as a reference to calculate the 1%/1mm, 2%/2mm and 3%/3mm gamma index for the DMLC deliveries. Results: For the tracked IMRT deliveries (550 MU/min, treatment time 13 min, Paddick conformity index CI=0.88), the 1%/1mm gamma index exceeded 79%, the 2%/2mm index exceeded 96% and it reached 100% at 3%/3mm for both sinusoidal trajectories. For the tracked VMAT deliveries (1100 MU/min max dose rate, 4.5 min, CI=0.84), the 1%/1mm gamma index exceeded 97% and it reached 100% at 2%/2mm for all trajectories. This constituted a marked dosimetric improvement for all cases compared to the untracked deliveries. The maximum deterioration from regular sin(t) to sin(t) with drift was 8.3/2.3 percentage points at 1%/1mm for IMRT/VMAT, indicating a limited influence of the FFF beam gradient on the dosimetric accuracy if delivery times and thus drifts are small.
Purpose/Objective: A complementary dual-modality imaging system, consisting of an orthogonal kilovolt (kV) fluoroscopy system and an independent MV portal imager, was used to perform intra-and inter-fraction verification of real-time tumor tracking (RTTT) on 8 lung and 3 liver cancer patients. To the authors' knowledge, for the first time accuracy of real-time tumor tracking was quantified by direct MV imaging on a patient cohort and compared with the standard verification by log files and orthogonal kV imaging. Materials and Methods: First, the dual-modality verification system was validated against an independent optical camera system hereby assessing its geometrical accuracy and precision. For all patients, a fiducial marker was implanted to facilitate the detection of the internal tumor motion. During dual-modality RTTT verification, marker detection was performed on both orthogonal kV X-ray (0.5 Hz) and planar MV images (7 Hz) to determine the internal position of the lesion. Tracking errors (TE) were defined by the difference between tumor position (related to the marker position) and the tracking field position. For the 3D reconstructed kV marker position, gimbals log files were used to retreive the tracking MV field position (XR-log file method). For MV images, a template-matching was performed using the reference MLC outline from planning. For each patient, the 95th percentile TE on the beams-eye view (BEV-TE 95 ) with EPID (EPID-PART) and XR-log file (XRlog-PART) for the part of the MV beams that contained a visible MV marker was calculated. For the total treatment, BEV-TE 95 and 95th percentile TE in 3D (3D-TE 95 ) were quantified using XR-log file information (XRlog-TOT). Results: Validation based on the optical camera system resulted in a sub-millimeter accuracy of -0.15±0.44 mm (PAN) and 0.29±0.35 mm (TILT) for the XR-log file method while TE were reproduced with a lower precision on EPID, i.e. -0.25±1.2 mm (PAN) and 0.35±1.1 mm (TILT). Results of dualmodality (EPID versus XRlog) verification of RTTT on patients are listed in table 1. BEV-TE95 between EPID-PART and XRlog-PART were not significantly different (paired t-test; p>0.05). Intra-and inter-fraction TE variations between both modalities (EPID, XRlog) were very similar. Resulting PTV margins did not differ between EPID and XRlog TE. Due to low marker contrast for particular MV beams (depending on tissue thickness along the beam axis), EPID RTTT verification was feasible for 65% of the treatment beams, with a strong advantage for beams orientated around the anteriorposterior axis.
